Transglutaminase 2 is associated with adverse colorectal cancer survival and represents a therapeutic target.
Malkomes P, Lunger I, Oppermann E, Lorenz J, Faqar-Uz-Zaman SF, Han J, Bothur S, Ziegler P, Bankov K, Wild P, et al. Cancer Gene Ther. 2023 Oct; 30(10):1346-1354. Epub 2023 Jul 13.